Key terms

About RLYB

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest RLYB news

Apr 17 7:15pm ET Buy Rating Affirmed for Rallybio Amid Significant Market Opportunity in FNAIT Treatment by TipRanks Apr 11 8:16am ET Rallybio price target lowered to $11 from $13 at Wedbush by TipRanks Apr 10 4:03pm ET Rallybio to partner with J&J on soultions to reduce risk of FNAIT by TipRanks Mar 26 1:55pm ET Rallybio’s RLYB212 Positioned to Transform FNAIT Prophylaxis Market, Analyst Maintains Buy Rating by TipRanks Mar 13 5:35pm ET Rallybio’s Clinical Advancements and Solid Financials Earn a Buy Rating from Analyst Ritu Baral by TipRanks Mar 13 6:25am ET Buy Rating Affirmed for Rallybio on Strong Drug Pipeline and Market Potential by TipRanks Mar 13 6:11am ET Rallybio price target lowered to $9 from $12 at H.C. Wainwright by TipRanks Mar 12 5:55pm ET Buy Rating Affirmed for Rallybio on Promising FNAIT Treatment and Financial Stability by TipRanks Mar 12 8:06am ET Rallybio reports Q4 EPS (50c), consensus (46c) by TipRanks Feb 07 9:03am ET Rallybio price target lowered to $13 from $14 at Wedbush by TipRanks Feb 07 8:02am ET Analysts’ Top Healthcare Picks: Rallybio (RLYB), Madrigal Pharmaceuticals (MDGL) by TipRanks Feb 07 6:31am ET Rallybio price target lowered to $8 from $16 at JMP Securities by TipRanks Feb 07 6:20am ET Wall Street Analysts Are Bullish on Top Healthcare Picks by TipRanks Feb 07 6:06am ET Rallybio price target lowered to $12 from $17 at H.C. Wainwright by TipRanks Feb 07 5:01am ET Rallybio downgraded to Hold from Buy at Jefferies by TipRanks Feb 07 4:14am ET Rallybio Announces Workforce Reduction and Restructuring Costs by TipRanks Feb 06 3:45pm ET Rallybio’s Strategic Focus and Strengthened Fiscal Position Garner Buy Rating by TipRanks Feb 06 8:03am ET Rallybio announces 45% reduction in workforce by TipRanks

No recent press releases are available for RLYB

RLYB Financials

1-year income & revenue

Key terms

RLYB Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

RLYB Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

The logo of Swiss bank UBS is seen at the company's headquarters in Zurich, Switzerland February 10, 2015. REUTERS/Arnd Wiegmann/File Photo
Arnd Wiegmann/Reuters
Switzerland says UBS may need more cash. The bank is fuming
Jamie Dimon, Chairman and Chief Executive officer (CEO) of JPMorgan Chase & Co. (JPM) speaks to the Economic Club of New York in Manhattan in New York City, U.S., April 23, 2024. REUTERS/Mike Segar
Mike Segar/Reuters
Jamie Dimon fears for the future of the free world and US debt
A bubble tea store operated by Sichuan Baicha Baidao in Shanghai, China, on April 23, 2024.
Raul Ariano/Bloomberg/Getty Images
Is the tea bubble bursting? ChaPanda shares plunge in Hong Kong IPO
People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.
Spencer Platt/Getty Images
Can markets make a comeback? That depends on tech earnings